Skip to main content
. 2022 Sep 13;12:914385. doi: 10.3389/fonc.2022.914385

Figure 5.

Figure 5

Subgroup analysis for progression-free survival and overall survival stratified by tumor size <10 cm (A, B) and ≥10 cm (C, D). T+S, transarterial chemoembolization+sorafenib; T+S+ICIs, transarterial chemoembolization+sorafenib+immune checkpoint inhibitors.